Virtual Empowered Relief for Chronic Pain

Sponsor
Stanford University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05057988
Collaborator
RTI International (Other)
75
1
1
27.7
2.7

Study Details

Study Description

Brief Summary

The purpose of the current pilot study is to examine a feasibility and the preliminary efficacy of Empowered Relief (ER) class when it is delivered 'virtually' to patients with chronic pain who take methadone or buprenorphine. The ER class is a single-session pain management class, which has demonstrated to be effective in improving pain and pain-related distress in patients with chronic low back pain, but its efficacy has not been examined in patients with chronic pain who take methadone or buprenorphine. Class participants will learn self-regulatory skills and develop a personalized plan to use the skills every day. The current study will examine a feasibility and participant's perception and satisfaction of this class at post-class. The study will also follow participants 3 months by administering 5 surveys (baseline, 2 weeks and 1 month, 2 months, and 3 months post-treatment) to determine whether the class confers the short-term and medium-term benefits across various aspects of health.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Empowered Relief class
N/A

Detailed Description

Some patients with chronic pain are on long-term opioid therapy. Methadone and buprenorphine are often used in long-term opioid therapy for chronic pain. Additionally, chronic pain is highly prevalent in people receiving methadone or buprenorphine for opioid use disorder (MOUD). It is observed that up to 68% of people with MOUD have chronic pain condition. Therefore, a large number of people taking methadone or buprenorphine will suffer from chronic pain, but they frequently face limited availability of clinicians offering non-pharmacological pain management programs. Thus, a brief internet-based pain relief skills program may be one option that can overcome such treatment barrier. A recent randomized control trial on patients with chronic low back pain has demonstrated that a single-session, 2-hour, pain management class (Empowered Relief; ER) was effective to improve pain and pain-related distress. The ER class consists of pain neuroscience education and self-regulatory skills. While the ER is a promising and scalable option, it is not yet tested in patients with chronic pain who take methadone or buprenorphine. The current proposed, single-arm, uncontrolled pilot project will determine a) a feasibility in this patient population, b) patients' perceptions and satisfaction of the ER class and c) preliminary efficacy to inform the design of a future, larger, controlled trial.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single interventionSingle intervention
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Virtual Empowered Relief for People With Chronic Pain Who Take Methadone or Buprenorphine
Actual Study Start Date :
Sep 8, 2021
Anticipated Primary Completion Date :
Sep 30, 2023
Anticipated Study Completion Date :
Dec 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Empowered Relief

Behavioral: Empowered Relief class
The participants will attend the Empowered Relief class online via Zoom. The class includes pain neuroscience education, as well as cognition, emotion, and physiologic self-regulation for people with chronic pain. Class participants will learn self-management skills and develop a personalized plan to use the skills every day. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.

Outcome Measures

Primary Outcome Measures

  1. Perceived usefulness/utility [once immediately after class]

    How useful was the information presented in the class?

  2. Participant satisfaction [once immediately after class]

    Please rate your overall satisfaction with the class

  3. Likelihood of using the skills [once immediately after class]

    How likely are you to use the skills and information you learned?

Secondary Outcome Measures

  1. Pain Bothersomness [At 1 month post-tx]

    How "bothersome" your pain had been during the previous week?

  2. PCS total scores [At 1 month post-tx]

    The Pain Catastrophizing Scale total scores

  3. Pain Intensity [At 1 month post-tx]

    How would you rate your pain on average in the past 7 days?

  4. Sleep disturbance [At 1 month post-tx]

    PROMIS-Sleep Disturbance short form T scores

Other Outcome Measures

  1. Pain interference [At 1 month post-tx]

    PROMIS-Pain Interference short form T scores

  2. Depression [At 1 month post-tx]

    PROMIS-Depression short form T scores

  3. Anxiety [At 1 month post-tx]

    PROMIS-Anxiety short form T scores

  4. Physical Function [At 1 month post-tx]

    PROMIS-Physical Function short form T Scores

  5. Global Impression of change [At 1 month post-tx]

    The global impression of change

  6. Craving [At 1 month post-tx]

    How much do you crave opiates now?

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age at least 18 years old

  • Chronic Pain (> 3 months)

  • Taking Methadone or Buprenorphine

  • English Fluency

Exclusion Criteria:
  • Pregnant,

  • Gross Cognitive Impairment,

  • Acute Suicidality,

  • Severe Depression

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stanford Pain Relief Innovations Lab Palo Alto California United States 27604

Sponsors and Collaborators

  • Stanford University
  • RTI International

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Beth Darnall, Associate Professor, Stanford University
ClinicalTrials.gov Identifier:
NCT05057988
Other Study ID Numbers:
  • IRB-60855
First Posted:
Sep 27, 2021
Last Update Posted:
Aug 3, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 3, 2022